R18 peptide reduces infarct volume following transient MCAO in the rat. R18 is neuroprotective when administered 60 min after the onset of MCAO. R18 reduces cerebral edema and improves functional outcomes. R18 appears more effective than the highly characterized NA-1 peptide. R18 is a potential neuroprotective treatment for stroke.